Skip to playerSkip to main content
  • 1 year ago
Minerva Neurosciences secured up to $200M in funding to advance its schizophrenia drug roluperidone. The financing follows FDA approval of its Phase 3 trial plan, aiming to treat negative symptoms unmet by current therapies.

Category

🗞
News

Recommended